Skip to main content

Advertisement

Table 3 Univariate analysis for predictors of pathologic complete response

From: S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial

Variables   n pCR n(%) Non-pCR n(%) Pvalue*
Ki-67 <30% 15 2 (13.3) 13 (86.7) 0.070
  ≥30% 18 8 (44.4) 10 (55.6)  
Initial tumor size ≤2 cm 7 4 (57.1) 3 (42.9) 0.083
  >2 cm 32 7 (21.9) 25 (78.1)  
Initial clinical stage II 22 5 (22.7) 17 (77.3) 0.482
  III 17 6 (35.3) 11 (64.7)  
Age, year < median (43) 20 7 (35.0) 13 (65.0) 0.480
  ≥ median (43) 19 4 (21.1) 15 (78.9)  
HR (10% of cut-off) Negative 11 4 (36.4) 7 (63.6) 0.694
  Positive 28 7 (25.0) 21 (75.0)  
  1. HR, hormone receptor. *Chi-square or Fisher’s exact test.